Officials from Pfizer/BioNTech reported the finding of their most-recent COVID-19 vaccine clinical trial. The Pfizer/BioNTech shows 100% efficacy and is handled well by adolescents ages twelve to fifteen.

The trial, concluded Wednesday, surveyed 2,260 subjects from ages twelve to fifteen. Results showed that the vaccine had a consistently strong antibody response in subjects one month after a final dosage. The trial gave 1,129 subjects placebo vaccines; among them 18 people contracted the virus. Among the 1,131 subjects who received true vaccines, none became infected.

Pfizer/BioNTech reports side and after effects identical to adult subjects such as pain at injection site, fever and fatigue after injection.

“We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” Pfizer CEO Albert Bourla said in a statement. “We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”


A week of political news in your in-box.
We find the news you need to know, so you don't have to.

Bourla’s comments were then seconded by BioBTech CEO Ugur Sahin who said, “We all long for a normal life. This is especially true for our children. The initial results we have seen in the adolescent studies suggest that children are particularly well protected by vaccination, which is very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant.”

Read more about:

Get the free uPolitics mobile app for the latest political news and videos

iPhone Android

Leave a comment